Immunological dimensions of neuroinflammation and microglial activation: exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 8, 2024

The increasing life expectancy has led to a higher incidence of age-related neurodegenerative conditions. Within this framework, neuroinflammation emerges as significant contributing factor. It involves the activation microglia and astrocytes, leading release pro-inflammatory cytokines chemokines infiltration peripheral leukocytes into central nervous system (CNS). These instances result in neuronal damage neurodegeneration through activated nucleotide-binding domain leucine-rich repeat containing (NLR) family pyrin protein 3 (NLRP3) nuclear factor kappa B (NF-kB) pathways decreased erythroid 2-related 2 (Nrf2) activity. Due limited effectiveness regarding inhibition neuroinflammatory targets using conventional drugs, there is challenging growth search for innovative therapies alleviating CNS diseases or even before their onset. Our results indicate that interventions focusing on Interleukin-Driven Immunomodulation, Chemokine (CXC) Receptor Signaling Expression, Cold Exposure, Fibrin-Targeted strategies significantly promise mitigate processes. approaches demonstrate potential anti-neuroinflammatory effects, addressing conditions such Multiple Sclerosis, Experimental autoimmune encephalomyelitis, Parkinson’s Disease, Alzheimer’s Disease. While findings are promising, immunomodulatory often face limitations due Immune-Related Adverse Events. Therefore, conduction randomized clinical trials matter mandatory, will pave way promising future development new medicines with specific therapeutic targets.

Language: Английский

---

Unraveling the therapeutic efficacy of resveratrol in Alzheimer’s disease: an umbrella review of systematic evidence

Nutrition & Metabolism, Journal Year: 2024, Volume and Issue: 21(1)

Published: March 19, 2024

Abstract Context Resveratrol (RV), a natural compound found in grapes, berries, and peanuts, has been extensively studied for its potential treating Alzheimer’s disease (AD). RV shown promise inhibiting the formation of beta-amyloid plaques (Aβ) neurofibrillary tangles (NFTs), protecting against neuronal damage oxidative stress, reducing inflammation, promoting neuroprotection, improving function blood–brain barrier (BBB). However, conflicting results have reported, necessitating comprehensive umbrella review systematic reviews to provide an unbiased conclusion on therapeutic effectiveness AD. Objective The objective this study was systematically synthesize evaluate meta-analysis investigating role AD using data from both human animal studies. Data sources extraction Of 34 examining association between that were collected, six included based specific selection criteria. To identify pertinent studies, search conducted English-language peer-reviewed journals without any restrictions publication date until October 15, 2023. carried out across multiple databases, including Embase, MEDLINE (PubMed), Cochrane Library, Web Science, Google Scholar, utilizing appropriate terms relevant research field. AMSTAR-2 ROBIS tools also used quality risk bias reviews, respectively. Two researchers independently extracted analyzed data, resolving discrepancies through consensus. note, adhered PRIOR checklist. analysis This presented robust evidence supporting positive impacts AD, irrespective mechanisms involved. It indeed indicated all unanimously concluded consumption can be effective treatment Conclusion exhibits promising benefiting individuals with various mechanisms. observed enhance cognitive function, reduce Aβ accumulation, protect BBB, support mitochondrial facilitate synaptic plasticity, stabilize tau proteins, mitigate neuroinflammation commonly associated Graphical abstract

Language: Английский

---

Photobiomodulation in experimental models of Alzheimer’s disease: state-of-the-art and translational perspectives

Alzheimer s Research & Therapy, Journal Year: 2024, Volume and Issue: 16(1)

Published: May 21, 2024

Abstract Alzheimer’s disease (AD) poses a significant public health problem, affecting millions of people across the world. Despite decades research into therapeutic strategies for AD, effective prevention or treatment this devastating disorder remains elusive. In review, we discuss potential photobiomodulation (PBM) preventing and alleviating AD-associated pathologies, with focus on biological mechanisms underlying therapy. Future directions guidance clinical practice non-invasive non-pharmacological therapy are also highlighted. The available evidence indicates that different paradigms, including transcranial systemic PBM, along recently proposed remote all could be promising AD. PBM exerts diverse effects, such as enhancing mitochondrial function, mitigating neuroinflammation caused by activated glial cells, increasing cerebral perfusion, improving glymphatic drainage, regulating gut microbiome, boosting myokine production, modulating immune system. We suggest may serve powerful intervention

Language: Английский

---

Targeting epigenetics: A novel promise for Alzheimer’s disease treatment

Ageing Research Reviews, Journal Year: 2023, Volume and Issue: 90, P. 102003 - 102003

Published: July 7, 2023

Language: Английский

---

SIRT1 signaling pathways in sarcopenia: Novel mechanisms and potential therapeutic targets

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 177, P. 116917 - 116917

Published: June 21, 2024

Sarcopenia is an aging-related skeletal disease characterized by decreased muscle mass, strength, and physical function, severely affecting the quality of life (QoL) elderly population. Sirtuin 1 (SIRT1), as a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylases, has been reported to participate in various signaling pathways exert protective effect on many human diseases. SIRT1 functioned important role occurrence progression sarcopenia through regulating key related protein homeostasis, apoptosis, mitochondrial dysfunction, insulin resistance autophagy muscle, including SIRT1/Forkhead Box O (FoxO), AMP-activated kinase (AMPK)/SIRT1/nuclear factor κB (NF-κB), SIRT1/p53, AMPK/SIRT1/peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), SIRT1/live B1 (LKB1)/AMPK pathways. However, specific mechanisms these processes have not fully illuminated. Currently, several SIRT1-mediated interventions preliminarily developed, such activator polyphenolic compounds, exercising calorie restriction. In this review, we summarized predominant involved therapeutic modalities targeting for prevention prognosis sarcopenia.

Language: Английский

---

Mind the Gap: Unraveling the Intricate Dance Between Alzheimer’s Disease and Related Dementias and Bone Health

Current Osteoporosis Reports, Journal Year: 2024, Volume and Issue: 22(1), P. 165 - 176

Published: Jan. 29, 2024

Abstract Purpose of Review This review examines the linked pathophysiology Alzheimer’s disease/related dementia (AD/ADRD) and bone disorders like osteoporosis. The emphasis is on “inflammaging”—a low-level inflammation common to both, its implications in an aging population. Recent Findings Aging intensifies both ADRD deterioration. Notably, patients have a heightened fracture risk, impacting morbidity mortality, though it uncertain if fractures worsen ADRD. Therapeutically, agents targeting pathways, especially Nuclear factor kappa-light-chain-enhancer activated B cells (NF-kB) TNF-α, appear beneficial for conditions. Additionally, treatments Sirtuin 1 (SIRT-1), known anti-inflammatory neuroprotective properties, are gaining attention. Summary interconnectedness AD/ADRD health necessitates unified treatment approach. By addressing shared mechanisms, we can potentially transform therapeutic strategies, enriching our understanding refining care society. article part series multiple manuscripts designed determine utility using artificial intelligence writing scientific reviews.

Language: Английский

---

Prospects of antidiabetic drugs in the treatment of neurodegenerative disease

Brain‐X, Journal Year: 2024, Volume and Issue: 2(1)

Published: Feb. 29, 2024

Abstract Neurodegenerative diseases (NDs) stand for a group of disorders characterized by the progressive loss neurons in brain and peripheral organs, resulting motor cognitive dysfunction. The global prevalence NDs, including Alzheimer's disease, Parkinson's Huntington's amyotrophic lateral sclerosis, is on rise globally, primarily due to an aging population, positioning NDs as increasing significant public health concern. Despite intensive research, few effective therapies that prevent or delay ND progression have been developed. Mounting evidence indicates one well‐defined risk factors type 2 diabetes mellitus, insulin resistance has also proven be related decline. Certain antidiabetic drugs, such glucagon‐like peptide‐1 receptor agonists, peroxisome proliferator‐activated gamma metformin, shown promise offering neuroprotective benefits alleviating symptoms beyond their glucose‐lowering effects. Although exact mechanisms remain elusive, these drugs offer promising novel strategy managing disorders. In this review, we first highlight specific effects multiple discuss main action treating NDs. These include reducing protein aggregation improving apoptosis, mitochondrial dysfunction, oxidative stress, neuroinflammation. Finally, summarize clinical trials evaluating

Language: Английский

---

Betaine alleviates doxorubicin-related cardiotoxicity via suppressing oxidative stress and inflammation via the NLRP3/SIRT1 pathway

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: 397(12), P. 9981 - 9990

Published: July 2, 2024

Language: Английский

---

Phytic Acid Extraction from Rice Bran with Acetic Acid : Optimization, Antioxidant Capacity and Mechanism Based on Cellular Metabolomics

LWT, Journal Year: 2025, Volume and Issue: unknown, P. 117394 - 117394

Published: Jan. 1, 2025

Language: Английский

---

Exploring the mechanism of Schisandra rubriflora in the treatment of polycystic ovary syndrome based on network pharmacology and molecular docking

Journal of Ovarian Research, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 28, 2025

Polycystic ovary syndrome (PCOS) is an endocrine disease associated with reproductive and metabolic abnormalities. The aim of this study was to elucidate the effects Schisandra rubriflora (S. rubriflora) on PCOS its related mechanisms using network pharmacology, molecular docking in vitro experiments. HERB database SwissTargetPrediction were used obtain active components targets S. rubriflora. Differentially expressed genes (DEGs) obtained by analyzing GSE54248 dataset. A protein-protein interaction constructed, topological analyses performed identify hub main bioactive components. binding abilities between key studied docking. Finally, models constructed KGN cells rat ovarian granulosa cells, respectively, regulatory schisandrin, a component rubriflora, investigated assays. total 14 ingredients 26 potential therapeutic treatment obtained. Bioinformatics suggested that treating IL-17 signaling pathway TNF pathway. affinities (schisandrin, wyerone, rugosal) (PTGS2, MMP9, MCL1, JUN) high. Schisandrin could attenuate lipopolysaccharide-induced inflammation, oxidative stress, apoptosis as well inhibit target expression activation. PTGS2, MCL1 JUN are for treat PCOS. Schisandrin, may be candidate

Language: Английский

---